Accordingly, our data from AML patients indicate that CD8+ T cells emerging after combined DNR and ARA-C chemotherapy are not only functionally capable of leukemia recognition but are also coupled with a novel population of Tregs with suppressive phenotype, Treg2 cells, recently described according to CD15s (28, 29). This evidence concerns the gene CD8A and acute myeloid leukemia.